In epilepsy, ketogenic dietary therapy is an established treatment, particularly for infantile, refractory, and metabolic epilepsies such as glucose transporter type 1 (GLUT1) deficiency and pyruvate dehydrogenase deficiency, where ketosis may reduce seizure frequency and severity, potentially via enhanced mitochondrial efficiency and dampened excitatory synaptic transmission, although mechanisms remain incompletely understood [67, 69, 70, 71]
Even when discounts are available, coverage is increasingly restricted by: Strict prior authorization requirements Step-therapy mandates Employer plan exclusions State Medicaid budget limitations Data also shows that many patients regain weight after stopping GLP-1 medications, reinforcing concerns that these drugs may function more as a long-term maintenance therapy rather than a finite treatment
Oscar Health Plan, Inc
Self-sourcing unlicensed medicines is strongly discouraged and may be unsafe
Love it!* Was this helpful
A fasting blood sample was drawn for determination of glucose luteinizing hormone (LH), follicle-stimulating hormone (FSH), androstenedione, dehydroepiandrosterone sulphate (DHEAS), total and free testosterone (T), and lipids, followed by a 2-h OGTT